Pharmacokinetic and pharmacodynamic characterization of OROS® and immediate-release amitriptyline

British Journal of Clinical Pharmacology

Volumn 48, Issue 1, 1999, Pages 71-78

  Gupta, Suneel K ^a   Shah, Jaymin C ^a   Hwang, Stephen S ^a  

^a ALZA CORPORATION   (United States)

Author keywords

Amitriptyline; Anticholinergic effects; Controlled release; Pharmacodynamics; Pharmacokinetics

Indexed keywords

AMITRIPTYLINE; DRUG METABOLITE; NORTRIPTYLINE; OROS; UNCLASSIFIED DRUG;

ADULT; ANTICHOLINERGIC EFFECT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DROWSINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG RELEASE; GAS CHROMATOGRAPHY; HUMAN; MALE; NIGHT; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SALIVA; TABLET; VISUAL ACUITY; VOLUNTEER; XEROSTOMIA;

ADULT; AMITRIPTYLINE; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CHEMISTRY, PHARMACEUTICAL; CHOLINERGIC ANTAGONISTS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEASIBILITY STUDIES; HUMANS; MALE;

EID: 0032988894     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00973.x     Document Type: Article

References (11)

1. 1 Therapeutic Drugs, ed. Sir Colin Dollery, Churchill Livingstone, Edinburgh, 1991; A95-A100.
2. 2 Schulz P, Turner-Tamiyasu K, Smith G, et al. Amitriptyline disposition in young and elderly men. Clin Pharmacol Ther 1983b; 33: 360-366.
3. 3 Cassano GB, Sjostrand SE, Hansson E. Distribution of 14C-labelled amitriptyline in the rat brain. Psychopharmacologia 1965; 8: 12-22.
4. 4 Bowden CL, Koslow SH, Hanin I, Mass JW, Davis JM, Robins E. Effects of amitriptyline and imipramine on brain amine neurotransmitter metabolites in cerebrospinal fluids. Clin Pharmacol Ther 1985; 37: 316-324.
5. 5 U'Prichard DC, Greenberg DA, Heninger GR. Tricyclic antidepressants: therapeutic properties and affinity for ( monoadrenergic receptor binding sites in the brain. Science 1978; 199: 197-198.
6. 6 Richelson E. Tricyclic antidepressants and H1 receptors. Mayo Clin Proc 1979; 54: 669-674.
7. 7 Nakano S, Hollister LE. Chronopharmacology of amitriptyline. Clin Pharmacol Ther 1983; 33: 453-459.
8. 8 Weise CC, Stein MK, Pereira-Ogan J, Csenalosi I, Rickels K. Amitriptyline once-daily vs. three times daily in depressed outpatients. Arch Gen Psychiatry 1980; 37: 556-560.
9. 9 Ghose K, Coppen A, Turner P. Autonomic actions and interactions of mianserin hydrochloride (Org. GB 94) and amitriptyline in patients with depressive illness. Psychopharmacol 1976; 49: 201-204.
10. 10 Knorring L, Mornstad H, Forsgren L, Holmgren S. Acute effects of different antidepressant drugs on saliva secretion and accommodation range. Pharmacopsychiatry 1986; 19: 106-110.
11. 11 Gupta S, Shah J, Guinta D, Hwang S. Multiple-dose pharmacokinetics and pharmacodynamics of OROS and immediate-release amitriptyline hydrochloride formulations. J Clin Pharmacol 1998; 38: 60-67.